|
CTCF expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.05399999994482E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.58678999999662E-05 |
| Normal-vs-Stage2 |
2.252100E-02 |
| Normal-vs-Stage3 |
1.49110000013941E-07 |
| Normal-vs-Stage4 |
9.5024000001942E-08 |
| Stage1-vs-Stage2 |
2.234400E-01 |
| Stage1-vs-Stage3 |
1.227370E-01 |
| Stage1-vs-Stage4 |
7.429900E-02 |
| Stage2-vs-Stage3 |
4.625900E-02 |
| Stage2-vs-Stage4 |
2.128000E-02 |
| Stage3-vs-Stage4 |
6.176200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.23130000032157E-07 |
| Normal-vs-AfricanAmerican |
1.961430E-03 |
| Normal-vs-Asian |
3.665900000005E-05 |
| Caucasian-vs-AfricanAmerican |
8.632800E-01 |
| Caucasian-vs-Asian |
9.189400E-01 |
| AfricanAmerican-vs-Asian |
9.016400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.14469999999523E-05 |
| Normal-vs-Female |
1.47299999997408E-06 |
| Male-vs-Female |
8.119600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.35499999999833E-05 |
| Normal-vs-Age(41-60Yrs) |
6.18009999953095E-07 |
| Normal-vs-Age(61-80Yrs) |
1.60254000000082E-05 |
| Normal-vs-Age(81-100Yrs) |
9.879000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.880400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.231600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.827200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.685200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.315600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.736000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.717500E-02 |
| Classical-VS-Follicular |
4.166800E-01 |
| Classical-VS-Other |
4.314000E-01 |
| Classical-VS-Normal |
3.94900000000309E-05 |
| Tall-VS-Follicular |
2.726800E-01 |
| Tall-VS-Other |
8.341000E-01 |
| Tall-VS-Normal |
3.75949999997793E-06 |
| Follicular-VS-Other |
6.974000E-01 |
| Follicular-VS-Normal |
8.26940000000498E-05 |
| Other-VS-Normal |
1.886150E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.54020000045996E-07 |
| Normal-vs-N1 |
6.58550003418412E-09 |
| N0-vs-N1 |
1.627570E-02 |
|
|
